Related Experiment Video

Updated: Jul 5, 2026

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

An oncogenic hub: beta-catenin as a molecular target for cancer therapeutics

K-I Takemaru1, M Ohmitsu, F-Q Li

  • 1Department of Pharmacological Sciences, State University of New York at Stony Brook, Stony Brook, NY 11794, USA. takemaru@pharm.stonybrook.edu

Handbook of Experimental Pharmacology
|May 21, 2008
PubMed

Insights

The Wnt/beta-catenin pathway regulates cell growth. Aberrant signaling drives colorectal cancer, making beta-catenin a key therapeutic target for novel anti-cancer drugs.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • The Wnt/beta-catenin signaling pathway is crucial for embryonic development and adult tissue homeostasis.
  • Beta-catenin stabilization activates downstream gene transcription, impacting cellular functions.
  • Aberrant Wnt/beta-catenin signaling is implicated in various human diseases, notably cancer.

Purpose of the Study:

  • To review the regulation of beta-catenin-dependent transcriptional activation.
  • To explore therapeutic strategies targeting the Wnt/beta-catenin pathway in cancer.
  • To highlight beta-catenin as a promising molecular target for anti-cancer drug development.

Main Methods:

  • Literature review focusing on Wnt/beta-catenin pathway regulation.
  • Analysis of the role of beta-catenin in cancer pathogenesis.
  • Discussion of therapeutic opportunities targeting protein-protein interactions.

Main Results:

  • Beta-catenin signaling is overactivated in over 70% of colorectal cancers.
  • This aberrant signaling promotes cancer cell proliferation, survival, and migration.
  • Targeting protein-protein interactions is a promising strategy for anti-cancer drug development.

Conclusions:

  • The Wnt/beta-catenin pathway is a significant driver of cancer.
  • Beta-catenin is a validated therapeutic target for colorectal and other cancers.
  • Developing drugs to disrupt beta-catenin interactions offers novel anti-cancer treatment avenues.

More Related Videos

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System05:45

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System

Published on: January 9, 2020

Related Concept Videos

Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
Catenins01:23

Catenins

Catenins are characterized by multiple binding domains and dynamic structures that allow them to function as linker proteins in cell junction complexes. All catenins, except α-catenin, contain a characteristic protein sequence called the armadillo repeat and are therefore also called armadillo proteins.
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the adherens...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...